European researchers analyzed the results of 10 past trials in 3,803 patients who took glucosamine, chondroitin or a placebo to treat arthritis in their hips or knees. They found neither supplement, taken either separately or together, did any better than a placebo.
Johnson & Johnson said it is in advanced talks to acquire Dutch biotech firm Crucell NV for €1.75 billion ($2.29 billion), a deal that would boost the American health care product maker's vaccine business.
Cardiometabolic disorders represent a combination of cardiometabolic risk factors including elevated fasting glucose, elevated triglycerides, low HDL-cholesterol levels, abdominal obesity, and hypertension.
Life Technologies Corporation announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies’ proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.
Bioo Scientific announced the availability of the MaxDiscovery Aspartate Transaminase (AST) and Lactate Dehydrogenase (LDH) Color Endpoint Assays which use a proprietary, innovative technology for visible detection of in vivo toxicity using only 5 µL of serum.
Forest Pharmaceuticals Inc. has agreed to pay more than $313 million and plead guilty to obstruction of justice, distribution of the then-unapproved drug Levothroid and illegal promotion of Celexa for use in treating children and adolescents suffering from depression.
Federal health advisers delivered a split opinion on whether to withdraw the diet pill Meridia due to evidence that it increases heart attack and stroke, with half voting to ban it and the others favoring new warnings and restricted distribution.
Cancer Research UK scientists have uncovered a new strategy that could be used by cancer cells to side step the body’s normal safety checks and become immortal – a key step for a cancer cell.
Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.
Way, way back when, in the very early days of my youth, singer/songwriter Carly Simon had a hit song, Anticipation. “We can never know about the days to come,” she sang. “But, we think about them, anyway.”
Research is showing that single cells differ in their expression even in tissues once considered homogenous. This could be especially useful knowledge in medical research.
Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, announced that a series of studies will be presented at the 50th ICAAC.
OXiGENE announced that positive results from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented at the 14th International Thyroid Congress.
Forward Pharma, A/S through its wholly owned German subsidiary Forward Pharma GmbH, announced initiation of its first phase 2 trial investigating efficacy and safety of different doses and regimes of FP187 in a double blind, placebo controlled trial.
Vical Incorporated announced the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax cytomegalovirus vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant recipients.